DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Please see below for Important Safety Information for DESCOVY.

Not all PrEP medication components are the same

DESCOVY® contains TAF, which more efficiently delivers tenofovir DP into PBMCs (including lymphocytes like CD4+ T cells) and macrophages vs TDF1-6

Graphic showing plasma half-life of tenofovir from TAF (tenofovir alafenamide) and TDF (tenofovir disoproxil fumarate) and levels in lymphocytes

TAF delivers more active drug to lymphocytes vs TDF, resulting in less off-target drug exposure.

There's no generic version of DESCOVY FOR PrEP®.

*Plasma half-life: TAF=30 minutes; TDF=0.41 minutes.
Tenofovir is converted into tenofovir DP in cells.

DP=diphosphate; PBMC=peripheral blood mononuclear cell; TAF=tenofovir alafenamide; TDF=tenofovir disoproxil fumarate.

You may also be interested in: